Caricamento...
Treatment of systemic sclerosis–associated interstitial lung disease: Lessons from clinical trials
Systemic sclerosis–associated interstitial lung disease remains a leading cause of mortality. Despite decades of clinical trials, the treatment effects of disease modifying anti-rheumatic drugs continue to be modest and there remains a great need for therapies that attenuate and hopefully ameliorate...
Salvato in:
| Pubblicato in: | J Scleroderma Relat Disord |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8168368/ https://ncbi.nlm.nih.gov/pubmed/35382226 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2397198320903208 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|